CTRP5 Antikörper (Internal Region)

Produktnummer ABIN350268

Produktdetails anti-CTRP5 Antikörper

Target: CTRP5 (C1QTNF5) (C1q and Tumor Necrosis Factor Related Protein 5 (C1QTNF5))

Bindungsspezifität: Internal Region

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser CTRP5 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (IHC)

Spezifität: Specific for CTRP5.

Kreuzreaktivität: Human, Maus, Ratte

Kreuzreaktivität (Details): Other species not yet tested.

Aufreinigung: IgG

Immunogen: A synthetic peptide from internal region of human CTRP5 conjugated to an immunogenic carrier protein was used as the antigen. The antigen is homologous in rat and mouse.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IHC, WB. A concentration of 10-50 μg,ml is recommended. The optimal concentration should be determined by the end user. Not yet tested in other applications.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Reconstitute in 500 μL of sterile water. Centrifuge to remove any insoluble material.

Handhabung: Avoid freeze and thaw cycles.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Haltbarkeit: 12 months

Details zu CTRP5

Target: CTRP5 (C1QTNF5) (C1q and Tumor Necrosis Factor Related Protein 5 (C1QTNF5))

Andere Bezeichnung: CTRP5 (C1QTNF5 Produkte)

Synonyme: C1QTNF5 antikoerper, wu:fb02c10 antikoerper, wu:fb02f05 antikoerper, zgc:112378 antikoerper, CTRP5 antikoerper, Ctrp5 antikoerper, C1q and tumor necrosis factor related protein 5 antikoerper, C1q and TNF related 5 antikoerper, C1QTNF5 antikoerper, c1qtnf5 antikoerper, C1qtnf5 antikoerper

Hintergrund: Defects in C1QTNF5 are a cause of late-onset retinal degeneration (LORD). LORD is an autosomal dominant disorder characterized by onset in the fifth to sixth decade with night blindness and punctate yellow-white deposits in the retinal fundus, progressing to severe central and peripheral degeneration, with choroidal neovascularization and chorioretinal atrophy. Subcellular location: Secreted,Vision,Complement C1q tumor necrosis factor-related protein 5, C1QTNF5

UniProt: Q9BXJ0